Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2017

Open Access 01-12-2017 | Review

Nano-based delivery of RNAi in cancer therapy

Authors: Yong Xin, Min Huang, Wen Wen Guo, Qian Huang, Long zhen Zhang, Guan Jiang

Published in: Molecular Cancer | Issue 1/2017

Login to get access

Abstract

Background

RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are capable of mediating effective RNAi with targeting potential, are attracting extensive interest.

Objective

This review presents an overview of the mechanisms of RNAi molecules in gene therapy and the different nanoparticles used to deliver RNAi molecules; briefly describes the current uses of RNAi in cancer therapy along with the nano-based delivery of RNA molecules in previous studies; and highlights some other carriers that have been applied in clinical settings. Finally, we discuss the nano-based delivery of RNAi therapeutics in preclinical development, including the current status and limitations of anti-cancer treatment.

Conclusion

With the growing number of RNAi therapeutics entering the clinical phase, various nanocarriers are expected to play important roles in the delivery of RNAi molecules for cancer therapeutics.
Literature
1.
Jema A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.CrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
3.
Tiram G, Scomparin A, Ofek P, Satchi-Fainaro R. Interfering cancer with polymeric siRNA Nanomedicines. J Biomed Nanotechnol. 2014;10:50–66.CrossRefPubMed
4.
Landesman-Milo D, Goldsmith M, Leviatan BS, Witenberg B, Brown E, Leibovitch S, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett. 2012;334(2):221–7.CrossRefPubMed
5.
Murchan PM, Bradford I, Palmer D, Townsend S, Harrison JD, Mitchell CJ, Macfie C. O.22 Value of preoperative and postoperative supplemental enteral nutrition in patients undergoing major gastrointestinal surgery. Clinical Nutrition. 1995;14(7014):8–8.
6.
Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010; 2:305.
7.
Melamed JR, Riley RS, Valcourt DM, Billingsley MM, Kreuzberger NL, Day ES. Quantification of siRNA duplexes bound to gold Nanoparticle surfaces. Methods Mol Biol. 2017;1570:1–15.CrossRefPubMed
8.
Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014;538:217–27.CrossRefPubMed
9.
Li X, Chen Y, Wang M, Ma Y, Xia W, Gu H. A mesoporous silica nanoparticle–PEI–fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials. 2013;34:1391–401.CrossRefPubMed
10.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2015;411(6836):494–8.CrossRef
11.
De FA, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443–53.CrossRef
12.
Martínez G, Forment J, Llave C, Pallás V, Gómez G. High-throughput sequencing, characterization and detection of new and conserved cucumber miRNAs. PloS One. 2011;6(5):e19523.
13.
14.
Lin H, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.CrossRef
15.
Jing L, Kai X, Roth JA, Ji L. Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochem Biophys Rep. 2016;6:16–23.
16.
Ohno SI, Itano K, Harada Y, Asada K, Oikawa K, Kashiwazako M, et al. Development of novel small hairpin RNAs that do not require processing by Dicer or AGO2. Mol Ther. 2016;24:1278–89.CrossRef
17.
Crocco P, Montesanto A, Passarino G, Rose G. Polymorphisms falling within putative miRNA target sites in the 3’UTR region of SIRT2 and DRD2 genes are correlated with human longevity. Gerontol A Biol Sci Med Sci. 2016;71(5):586–92.CrossRef
18.
Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016;351(6280):1454.CrossRefPubMedPubMedCentral
19.
Katoh M, Terada M. Oncogenes and tumor suppressor genes. Gastric Cancer. 1993:196–208.
20.
Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a bcr/abl fusion gene by rna interference (rnai). Oncogene. 2002;21(37):5716–24.CrossRefPubMed
21.
Cioca D, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in humanmyeloid leukemia cell lines. Cancer Gene Ther. 2003;10(2):125–33.CrossRefPubMed
22.
Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003;545:144–50.CrossRefPubMed
23.
Zhao J, Feng SS. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine. 2015;10(14):2199–228.CrossRefPubMed
24.
Wang K, Zhang X, Liu Y, Liu C, Jiang B, Jiang YY. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials. 2014;35(30):8735–47.CrossRefPubMed
25.
Scomparin A, Tiram G, Satchi-Fainaro R. Nanoscale-based delivery of RNAi for cancer therapy. In: Erdmann VA, Barciszewski J, editors. DNA and RNA nanotechnologies in medicine. Diagnosis and treatment of diseases. Berlin: Springer; 2013:349–372.
26.
Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous Gene by systemic Administration of Modified SiRNAs. Nature. 2004;432:173–8.CrossRefPubMed
27.
de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443–53.CrossRefPubMed
28.
29.
Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–84.CrossRefPubMed
30.
31.
Nagal A, Singla R K. Nanoparticles in different delivery systems: a brief review. Indo Global Journal of Pharmaceutical Sciences, 2013;3(2):96–106.
32.
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.PubMed
33.
Ragelle H, Vandermeulen G, Préat V. Chitosan-based siRNA delivery systems. J Control Release. 2013;172(1):207–18.CrossRefPubMed
34.
35.
Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by fluorescence fluctuation spectroscopy and single photon emission comp. J Control Release. 2009;138(2):148–59.CrossRefPubMed
36.
37.
Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem. 2008;19(11):2156–62.CrossRefPubMed
38.
39.
Torrecilla J, Del Pozo-Rodríguez A, Solinís MÁ, Apaolaza PS, Berzal-Herranz B, Romero-López C, et al. Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). Colloids Surf B Biointerfaces. 2016;146:808–17.CrossRefPubMed
40.
Szabo P. Formulation and stability aspects of Nanosized solid drug delivery systems. Curr Pharm Des. 2015;21:3148–57.CrossRefPubMed
41.
Pang J, Luan Y, Yang X, Jiang Y, Zhao L, Zong Y, et al. Functionalized mesoporous silica particles for application in drug delivery system. Mini Reviews in Medicinal Chemistry. 2012;12(8):775–88.CrossRefPubMed
42.
Wu SH, Mou CY, Lin HP. Synthesis of mesoporous silica nanoparticles. Chem Soc Rev. 2013;42(9):3862–75.CrossRefPubMed
43.
Jing CX, Zhang H. Inhibition of VEGF expression and SMMC 7721 cell growth by VEGFsiRNA. Chin J Pathophysiology. 2006;22(4):771–5.
44.
Conde J, Ambrosone A, Sanz V, Hernandez Y, Marchesano V, Tian F, et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano. 2012;6(9):8316–24.CrossRefPubMed
45.
Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26(1):83–90.CrossRefPubMed
46.
Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235–40.CrossRefPubMed
47.
Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4(7):3689–96.CrossRefPubMed
48.
Jang SC, Kim OY, Yoon CM, Choi DS, Roh TY, Park J, et al. Bioinspired exosome mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. 2013;7:7698–710.CrossRefPubMed
49.
Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125–40.PubMedPubMedCentral
50.
American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
51.
Saini V, Kamboj S, Bala S, Nair AB. Nanocarriers as an emerging platform for cancer therapy. Int J Nat Prod Sci. 2012;1(12):751–60.
52.
Lunavat TR, Jang SC, Nilsson L, Park HT, Repiska G, Lässer C, et al. RNAi delivery by exosome-mimetic nanovesicles - implications for targeting c-Myc in cancer. Biomaterials. 2016;102:231.CrossRefPubMed
53.
Wu Y, Wang W, Chen Y, Huang K, Shuai X, Chen Q, et al. The investigation of polyer-siRNA nanoparticle for gene therapy of gastric cancerin vitro.InterJ. Nanomedicine. 2010;5:129–36.CrossRef
54.
Huschka R, Barhoumi A, Liu Q, Roth JA, Ji L, Halas NJ. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano. 2012;6(9):7681–91.CrossRefPubMedPubMedCentral
55.
Mohammadi M, Salmasi Z, Hashemi M, Mosaffa F, Abnous K, Ramezani M. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells. Int J Pharm. 2015;485:50–60.CrossRefPubMed
56.
Liu X, Liu L, Xu Q, Wu P, Zuo X, Ji A. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther. 2012;12:573–80.CrossRefPubMed
57.
Jr CR, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 2007;6(5):373–90.CrossRef
58.
Xie Y, Murray-Stewart T, Wang Y, Yu F, Li J, Marton LJ, et al. Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy. J Control Release. 2016;246:110–9.CrossRefPubMed
59.
Crew E, Tessel MA, Rahman S, Razzak-Jaffar A, Mott D, Kamundi M, et al. MicroRNA conjugated gold nanoparticles and cell transfection. Anal Chem. 2012;84(1):26–9.CrossRefPubMed
60.
61.
Tang D. Research progress on the development of the strategies for siRNAs delivery in vivo. J Biomed Eng. 2012;29(4):775–9.
62.
63.
Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(2):295–304.CrossRefPubMed
64.
Frisch J, Orth P, Venkatesan JK, Rey-Rico A, Schmitt G, Kohn D, et al. Genetic modification of human peripheral blood aspirates using recombinant Adeno-associated viral vectors for Articular cartilage repair with a focus on Chondrogenic transforming growth factor-β Gene delivery. Stem Cells Transl Med. 2017;6:249–60.CrossRefPubMed
65.
66.
Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005;5(5):323–31.CrossRefPubMed
67.
68.
Foged C. siRNA delivery with lipid-based systems: promises and pitfalls. Curr Top Med Chem. 2012;12(2):97–107.CrossRefPubMed
69.
Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850–62.CrossRefPubMed
70.
71.
Urbanklein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine(PEI)-complexed sirna in vivo. Gene T- her. 2005;12(5):461–6.CrossRef
72.
Mccarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26(26):154–8.PubMedPubMedCentral
73.
Lage H, Krühn A. Bacterial delivery of RNAi effectors: transkingdom RNAi. J Vis Exp. 2010;(42). doi: 10.​3791/​2099.
74.
Love TM, Moffett HF, Novina CD. Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol. 2008;121(2):309–19.CrossRefPubMed
75.
O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10(2):111–22.CrossRefPubMed
76.
Weinstein S, Peer D. RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology. 2010;21(23):232001–232013(13).CrossRefPubMed
Metadata
Title
Nano-based delivery of RNAi in cancer therapy
Authors
Yong Xin
Min Huang
Wen Wen Guo
Qian Huang
Long zhen Zhang
Guan Jiang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-017-0683-y

Other articles of this Issue 1/2017

Molecular Cancer 1/2017 Go to the issue

Research

Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling

Review

Cdk5 links with DNA damage response and cancer

Review

Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells

Research

DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis

Research

Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes

Research

Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits